INTRODUCTION
Vanishing white matter disease (VWM, OMIM 306896), also called childhood ataxia with central nervous system hypomyelination or eukaryotic translation initiation factor 2B (eIF2B)-related disorder, is one of the most prevalent inherited childhood leukoencephalopathies. The phenotype varies from a severe antenatal form to a mild adultonset variant. The classical phenotype is characterized by early childhood onset of progressive neurological regression, usually with episodic deterioration provoked by febrile infection, minor head trauma or sudden fright. [1] [2] [3] Death occurs after a period, which varies from several years to decades. The remarkable feature in brain magnetic resonance imaging is symmetric and diffuse fluid-like signal in cerebral white matter, which is consistent with the cystic degeneration found by pathological analysis. 4 VWM is inherited in an autosomal recessive manner. Mutations in the five subunits of eIF2B (a, b, g, d and e), encoded by EIF2B1-5, were identified in VWM in 2001-2002 (Leegwater et al.; 5 van der Knaap et al. 6 ). The eIF2B complex has a key role in mRNA translation initiation through its guanine nucleotide exchange (GEF) activity. The eIF2B complex promotes guanosine diphosphate (GDP)/guanosine triphosphate (GTP) exchange on eIF2, and is required to regenerate active GTP-eIF2 from its inactive GDP-bound form to allow continued translation initiation. In the GTP-bound state, eIF2 recruits the initiator Met-tRNA to the 40S subunit for translation initiation. Although the pathogenic pathway from the eIF2B defects to the degeneration of cerebral white matter is far from understood, VWM is considered the first human hereditary disease caused by defects in the initiation of protein synthesis. 7, 8 To date, 4120 VWM mutations have been identified in EIF2B1-5. More than half were found in EIF2B5 (57%), followed by EIF2B4 (16%), EIF2B2 (16%), EIF2B3 (7%) and EIF2B1 (4%). [9] [10] [11] Most of the published studies were carried out in the Caucasian population. Since 2006, 12 Chinese children have been diagnosed with VWM that was confirmed by EIF2B1-5 gene sequencing. 12 A total of 16 EIF2B mutations were found (Table 1) in the Chinese patients, with 11 in EIF2B5 (68.8%), 3 in EIF2B3 (18.8%) and 2 in EIF2B2 (12.5%). Eight mutations were not previously reported in other populations, and of these four are in EIF2B5.
Of the five eIF2B subunits, eIF2Be is the largest and the most important, as it exhibits GEF activity when expressed alone. eIF2Be is encoded by EIF2B5. EIF2B5 mutations impair the function of the eIF2B complex in diverse ways, including causing the formation of truncated proteins, disrupting holocomplex assembly and causing partial loss of GEF activity. [13] [14] [15] The EIF2B5 mutations that have been functionally investigated are p.Val73Gly, p.Thr91Ala, p.Leu106Phe, p.Arg113His, p.Arg195His, p.Arg299His, p.Arg315His, p.Arg339Pro, p.Gly386Val, p.Val430Ala and p.Trp628Arg. 13, [16] [17] [18] [19] [20] The EIF2B5 mutations we found in Chinese patients, which were not previously reported in other population, were p.Asp62Val (c.185A4T), p.Cys335Ser (c.1004G4C), p.Asn376Asp (c.1126A4G) and p.Ser610-Asp613del (c.1827-1838del), they locate from N-through C-terminus of eIF2Be. 12 Analysis of how these mutations give rise to the functional defects will help in define the critical sites in eIF2Be involved in its function and regulation. Information about the functional defects that result from specific mutations will be helpful for delineating the genotype-phenotype correlations.
In this study, we analyzed how these EIF2B5 mutations, which recently described in Chinese patients, resulted in functional defects in eIF2Be. Mutants were compared with wild type in terms of the level of eIF2Be protein, interaction of the mutant subunit with the others to form the eIF2B complex, interaction with the eIF2 substrate, the phosphorylation level of eIF2Be at the regulatory GSK3 (glycogen synthase kinase-3) site, and the GEF activity. In addition to the four recently described mutations, p.Arg269X, which was reported in 2008 (Maletkovic et al. 11 ), was also studied. We summarized the phenotypes of four Chinese children who harbored these EIF2B5 mutations, and searched for genotype-phenotype correlations.
MATERIALS AND METHODS

Patients
The research was approved by Medical Ethics Committee of Peking University First Hospital. Clinical diagnosis of VWM was based on the criteria of van der Knaap et al. 21 EIF2B1-5 mutation screening was performed for each patient and the parents. Of 12 confirmed VWM patients, EIF2B5 mutations not previously reported in other population were found in four. Data on these patients are in Table 2 .
Expression vectors
Expression vectors for full-length wild-type human eIF2Ba-e are as described previously. 13 The eIF2Ba-d complementary DNA in expression vectors was N-terminally tagged with Myc, and the vector with full-length eIF2Be complementary DNA was tagged with both Myc and hexahistidine (His 6 ) at the N-terminus. eIF2Be mutations (p.Asp62Val, p.Arg269X, p.Cys335Ser, p.Asn376Asp and p.Ser610-Asp613del) were generated using the Quick-change site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions, and were confirmed by sequencing.
Cell culture, transfection, lysis and pull-down purification Human embryonic kidney 293 (HEK 293) cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Transfection with the mutants or wild type was conducted using Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. Cells were lysed 48 h after transfection. To study eIF2Ba-e complex assembly, the interaction with eIF2, phosphorylation level or the GEF activity, recombinant complex containing HisMyc-tagged eIF2Be was purified from HEK 293 lysates containing endogenous eIF2B. Purification was by pull-down with Ni-nitrilotriacetic acid-agarose (Qiagen, Shanghai, China). Pulled-down protein was analyzed by western blot, with anti-Myc to assess the eIF2Ba-e complex formation, anti-eIF2 for eIF2B-eIF2 interaction, and anti-eIF2BeSer 540 (P) for phosphorylation level of eIF2BeSer 540 .
Quantitative real-time reverse transcriptase-PCR To determine whether transcript levels of the mutants resulted in reduced protein, quantitative real-time reverse transcriptase-PCR was performed. Total RNA was isolated from transfected HEK 293 cells with TRIzol reagent (Invitrogen). We used the TaqMan probe technology for analysis. PCR products are located in 5¢-upstream of both two mutations, primers are 5¢-CTTCTTCCCCATCTCCAAGGA-3¢ (sense) and 5¢-TACACCTGTGGCAGTCAGGAAT-3¢(anti-sense). TaqMan probe for EIF2B5, with 5¢-FAM and 3¢-TAMRA, is 5¢-CAGCCTC GGGTCCTCTTGCCC-3¢. Glyceraldehyde 3-phosphate dehydrogenase is used as internal control, primers pairs are 5¢-CAGTCAGCCGCATC TTCTTTT-3¢(sense) and 5¢-GTGACCAGGCGCCCAATAC-3¢(antisense), TaqMan probe for glyceraldehyde 3-phosphate dehydrogenase is 5¢-CGTCGCCAGCCGAGCCACA-3¢.
GEF activity measurement
The activity of recombinant eIF2B complex, with His-Myc-tagged eIF2Be, was tested by purification by pull-down as described above. GTP/GDP exchange activity was measured using the standard assay, 13 eIF2Be mutations identified in Chinese patients with VWM X Leng et al with purified human eIF2.[ 3 H]GDP as substrate. Amounts of purified recombinant eIF2B complex were determined by quantitative western blot using the LiCor Odyssey system, (LI-COR Biotechnology-UK Ltd, Cambridge, UK) and the amounts of protein in GEF activity assays adjusted accordingly.
RESULTS
All five eIF2Be mutations decrease eIF2B GEF activity
To determine whether the eIF2Be mutations affected GEF activity, we measured this activity using purified recombinant eIF2B heteropentamers containing either mutant or wild-type eIF2Be. All five mutant eIF2Be consistently displayed decreased GEF activity compared with the wild type. The impairment varied from mild to severe. p.Arg269X and p.Ser610-Asp613del mutants displayed the lowest GEF activity, followed by p.Cys335Ser, p.Asn376Asp and p.Asp62Val (Figure 1 ).
The p.Arg269X and p.Ser610-Asp613del mutations significantly reduce eIF2Be protein level Vectors containing the five eIF2Be variants were transfected into HEK 293 cells for analysis by in vitro studies. The levels of eIF2Be-Asp62Val, eIF2Be-Cys335Ser and eIF2Be-Asn376Asp were similar to the level of wild-type eIF2Be, while eIF2Be-Arg269X and eIF2Be-Ser610-Asp613del were substantially reduced and were almost undetectable, which shown as very weak bands only when exposure was enhanced ( Figure 2 ). To understand whether the reduction in the mutant protein resulted from a decrease in mRNA level, quantitative realtime reverse transcriptase-PCR was conducted. The level of the mRNA for p.Arg269X was comparable to the wild-type mRNA, while signal for p.Ser610-Asp613del mRNA was not detected suggesting that its stability may be impaired.
Interaction of eIF2Be with other eIF2B subunits is not affected by the p.Asp62Val, p.Cys335Ser or p.Asn376Asp mutations eIF2Be alone can mediate GEF, but GEF activity is greatly enhanced when eIF2Be combines with the other four subunits to form a heteropentamer. 22, 23 The binary subcomplex of eIF2Be and eIF2Bg is needed for holocomplex formation. Without the g subunit, eIF2Be was unable to bind a complex of eIF2Babd. To determine whether the mutations affected the assembly of eIF2B complex, we compared eIF2Beg subcomplex formation between the mutants and the wild type. HEK 293 cells were co-transfected with His-Myc-tagged eIF2Be and Myc-tagged eIF2Bg. Protein pulled down with Ni-nitrilotriacetic acid-agarose, containing recombinant eIF2Beg, was analyzed by western blot, using anti-Myc. The amount of the pulled-down Myctagged eIF2Bg was comparable between the three missense mutations and the wild type, while no Myc-tagged eIF2Bg was pulled down from p.Arg269X or p.Ser610-Asp613del transfected cells (Figure 3) . Therefore, p.Asp62Val, p.Cys335Ser and p.Asn376Asp did not affect the assembly of the eIF2Beg subcomplex. The failure to detect Figure 1 Effects of five EIF2B5 mutations on the eukaryotic translation initiation factor 2B (eIF2B) guanine nucleotide exchange (GEF) activity. GEF activity was measured using purified recombinant eIF2B heteropentamers containing either mutant or wild-type eIF2Be (n¼3). All five mutant eIF2Be consistently displayed decreased GEF activity compared with the wild type. Figure 2 Protein expression of five mutant eukaryotic translation initiation factor 2B (eIF2B)e. The five eIF2Be variants were transfected into human embryonic kidney 293 (HEK 293) cells for analysis by in vitro studies (n¼5). The levels of eIF2Be-Asp62Val, Cys335Ser and Asn376Asp were similar to the level of wild-type eIF2Be, while eIF2Be-Arg269X and Ser610-Asp613del were substantially reduced and were almost undetectable.
eIF2Be mutations identified in Chinese patients with VWM X Leng et al pulled-down eIF2Bg with p.Arg269X and p.Ser610-Asp613del probably reflects the greatly reduced amount of protein in the lysate coupled, perhaps, with inability of the truncated polypeptide to bind stably to eIF2Bg. We further studied whether the mutations affected formation of the eIF2B heteropentamer by expressing the HisMyc-tagged eIF2Be subunit together with all four other Myc-tagged subunits. Similar amounts of Myc-tagged a, b, g, d or e subunits were pulled down from cells with the three missense mutations, and the wild-type eIF2Be (Figure 3 ).
The p.Asp62Val, p.Cys335Ser and p.Asn376Asp mutations do not affect the binding of eIF2B complex to eIF2 Binding of eIF2B complex to eIF2 (its substrate) is critical for its GEF activity. The eIF2 trimeric complex consists of a, b and g subunits. Phosphorylation of eIF2a can inhibit the GEF activity of eIF2B, and is an important regulation mechanism for eIF2B. 23, 24 We studied whether the binding of eIF2B complex to eIF2 or eIF2a (P) was affected by the three missense mutations. HEK 293 cells were co-transfected with HisMyc-tagged eIF2Be and the other four Myc-tagged eIF2B subunits. Protein pulled down with Ni-nitrilotriacetic acid-agarose, containing recombinant eIF2B, was analyzed by western blot with anti-eIF2 or anti-eIF2a (P). The amount of eIF2 and eIF2a (P), was similar for the three missense mutations and the wild type ( Figure 4) . Thus, the reduced activity of the missense mutants is not due to impaired binding to substrate or enhanced binding to eIF2a(P).
The p.Asp62Val, p.Cys335Ser and p.Asn376Asp mutations do not affect the phosphorylation level of eIF2BeSer 540 Phosphorylation of eIF2Be itself is one of the mechanisms that regulates its function, and eIF2BeSer 540 , which is the target of GSK3, is a key regulatory phosphorylation site in eIF2Be. [23] [24] [25] To determine whether the mutations changed the phosphorylation level of the GSK-3 site, we analyzed purified His-Myc-tagged eIF2Be by western blot, using anti-eIF2BeSer 540 (P) and anti-eIF2Be, and calculated a semi-quantitative eIF2BeSer 540 (P)/eIF2Be ratio for the mutants and the wild type. None of three missense mutations, p.Asp62Val, p.Cys335Ser and p.Asn376Asp, affected the phosphorylation level of eIF2Be Ser 540 ( Figure 5 ).
DISCUSSION
eIF2Be is a multidomain protein (721 amino acids) that is widely expressed in eukaryotic cells. It is the largest subunit in the eIF2B heteropentamer complex, and contains the catalytic domain. 26 The C-terminal residues (518-712) of eIF2Be contain a minimal functional unit that interacts with eIF2, and exhibits GEF activity. Within the C-terminal region, residues 581-712 can interact with eIF2, and residues 518-580 are required for GEF activity, and are thus considered the 'catalytic center' . The role of the N-terminal 500 residues of eIF2Be is unclear, but is probably involved in interaction with the other eIF2B subunits. 23, 24 Measurement of eIF2B GEF activity in patients' transformedlymphocytes was reported to be an important tool for the diagnosis of eIF2B-related disorders. 27 We found that all these recently described eIF2Be mutations in Chinese VWM children resulted in a decrease in eIF2B complex GEF activity. The p.Arg269X and p.Ser610-Asp613del Figure 3 Effects of three EIF2B5 mutations on the Interaction of eukaryotic translation initiation factor 2B (eIF2B)e with other eIF2B subunits. Human embryonic kidney 293 (HEK 293) cells were co-transfected with His-Myctagged eIF2Be and Myc-tagged eIF2Bg. Protein pulled down with Ninitrilotriacetic acid (NTA)-agarose, containing recombinant eIF2Beg, was analyzed by western blot, using anti-Myc. p.Asp62Val, p.Cys335Ser and p.Asn376Asp did not affect the assembly of the eIF2Beg subcomplex (Figure 3a) . Then we expressed the His-Myc-tagged eIF2Be subunit together with all four other Myc-tagged subunits. Similar amounts of Myc-tagged a, b, g, d or e subunits were pulled down from cells with the three missense mutations and the wild type (Figures 3b and c) . The failure to detect pulleddown other eIF2B subunits with p.Arg269X and p.Ser610-Asp613del is probably because of the significantly reduced amount of protein in the lysate (n¼4). Figure 4 Effects of three EIF2B5 mutations on the binding of eukaryotic translation initiation factor 2B (eIF2B) complex to eIF2. Human embryonic kidney 293 (HEK 293) cells were co-transfected with His-Myc-tagged eIF2Be and the other four Myc-tagged eIF2B subunits. Protein pulled down with Ni-nitrilotriacetic acid (NTA)-agarose, containing recombinant eIF2B, was analyzed by western blot with anti-eIF2 or anti-eIF2a (P). The amount of eIF2 and eIF2a (P), was similar for the three missense mutations and the wild type (n¼3). Figure 5 Phosphorylation level of eukaryotic translation initiation factor 2B (eIF2B)eSer 540 with three missense mutations. We analyzed purified HisMyc-tagged eIF2Be by western blot, using anti-eIF2BeSer 540 (P) and antieIF2Be, and calculated a semi-quantitative eIF2BeSer 540 (P)/eIF2Be ratio for the mutants and the wild type. None of three missense mutations, p.Asp62Val, p.Cys335Ser and p.Asn376Asp, affected the phosphorylation level of eIF2Be Ser 540 (n¼3). eIF2Be mutations identified in Chinese patients with VWM X Leng et al mutants displayed the lowest GEF activity, followed by p.Cys335Ser, p.Asn376Asp and p.Asp62Val. Therefore, all the eIF2Be mutations impaired the eIF2Be catalytic function, and consequently affected normal translation initiation.
Our data showed that both p.Arg269X and p.Ser610-Asp613del resulted in significant produce of stable eIF2Be, either because of a decrease in mRNA level or posttranslational degradation. Therefore, these two mutations lead to an almost loss-of-function and should be considered null mutations. The other three mutations did not change the protein level. As all of them are in the N-terminus, it is unlikely that they impair the catalytic function of eIF2Be by interfering directly with GEF activity or substrate binding. On the basis of proposed pathways for regulating eIF2B, we next attempt to define the reason for the decreased GEF activity in the p.Asp62Val, p.Cys335Ser and p.Asn376Asp mutants.
Although eIF2Be itself exhibits GEF activity, the formation of a fivesubunit eIF2B complex stimulates GEF activity 10-to 40-fold in yeast or mammalian cells. 22 The N-terminus of eIF2Be is considered to be critical for complex formation. The subcomplex eIF2Beg is reported to be required for holocomplex formation. We examined whether the N-terminal mutations interfered with assembly of eIF2Beg or the heteropentamer. All the mutants examined here efficiently formed both types of complex indicating that p.Asp62, p.Cys335 and p.Asn376 in eIF2Be are probably not critical residues for subunit interaction.
Direct phosphorylation of eIF2Be has been described for mammalian eIF2B, which is another way of functional regulation. 23, 24, 28 At least four protein kinases have been found to phosphorylate eIF2Be, including CK1 (casein kinase1), CK2 (casein kinase2), DYRK (dual-specificity tyrosine phosphorylated and regulated kinase) and GSK3. Of these, GSK3 is thought to have greatest effect on regulation of eIF2B activity. Phosphorylation of human eIF2Be by GSK3 at Ser 540 inhibits eIF2B activity. In the presence of insulin, GSK3 activity is inhibited, thus eIF2Be is dephosphorylated and therefore becomes more active. In our study, the p.Asp62Val, p.Cys335Ser and p.Asn376Asp mutations showed no effects on the phosphorylation of the GSK3 site. Their N-terminal location makes it unlikely that these mutations affect the other known phosphoryraltion sites directly, as most of them are in the C terminus. Indirect effects or changes in other potential phosphorylation sites are possible.
Another mechanism of regulation is phosphorylation of the eIF2a subunit. Phosphorylated eIF2a-Ser 51 has a high affinity for eIF2Be, but instead of promoting GEF function, the increased affinity reduces the GTP/GDP exchange function, and thus inhibits eIF2B activity. 23 We previously showed that certain mutants in eIF2Be lead to stronger association with eIF2a, perhaps explaining the lower GEF activity of complexes containing these mutants. 13 We examined whether these missense mutations affect eIF2Be binding to either total eIF2 or phosphorylated eIF2. Our data showed that the heteropentamer containing mutant eIF2Be had binding similar to the wild type, so these mutations are unlikely abolish regulation of eIF2B by eIF2a.
The phenotype of VWM varies from a severe antenatal form to a mildest adult-onset variant. More than 120 eIF2Ba-e mutations have been found in VWM since 2001 (Maletkovic et al. 11 ). Nonsense mutations are rare and observed only in heterozygotes, associated with a missense mutation allele. The correlation between eIF2B genotype and phenotype is not clear. It is reported that the disease severity is not correlated with either the type of the subunit mutated, or the position of the mutation within the protein. 29 Recently p.Arg113His in the e and p.Glu213Gly in the b subunits have been associated with milder phenotypes, and a relationship between severe phenotype with early infantile onset and p.Arg195His in the e has been found. 29, 30 One hypothesis is that severe phenotypes occur in the presence of homozygotic mutations in highly conserved regions, with mutations in non-conserved amino acids leading to mild phenotype. However, the genotype-phenotype correlation is not consistent.
All patients in our study had the classical phenotype, with disease onset between 2 and 6 years of age. However, even within this phenotype, patients differed from each other in age of onset, disease progression and clinical manifestations. Horzinski et al. 27 found a weak correlation between GEF activity measured in the eIF2B-mutated lymphoblastoid cell line and age at disease onset. Patient 2, with compound heterozygous mutations p.Arg269X/p.Cys335Ser, showed the most severe phenotype. Disease symptoms began as early as 2 years of age, with mild developmental delay even before disease onset. As p.Arg269X is almost functional null, the allele with p.Cys335Ser was the only copy available to produce eIF2Be in this patient. Although as a non-conserved amino acid, eIF2Be-Cys335Ser allele resulted in a significant decrease in eIF2B GEF activity, at only half the activity of wild type, and may not provide enough protection from the severe phenotype. GEF activity was also reported to be significant low (39 ± 7% of control) in a patient's lymphoblast with p.Arg269X heterozygous mutation. 27 Patient 1, with an onset at around 3 years of age, harbored the heterozygous genotype p.Asn376Asp/p.Ser447Leu. p.Ser447Leu was reported in a patient with the most severe antenatal form of VWM, who had a compound heterozygous genotype with another missense mutation, thus may have contributed to the severe phenotype. 31 eIF2Be-Asp376Asp, which had GEF activity that was approximately 80% of wild type, is probably not related to a severe classical phenotype in the classical form. Patient 3 showed the mildest phenotype, with disease symptoms beginning after 6 years of age, and progressing relatively slowly. This patient harbored the mutations p.Asp62Val/p.Arg339Pro. p.Arg339Pro is reported to lead to a significant reduction in GEF activity to approximately 30% of wild type, 13 while we found only slightly reduced activity for p.Asp62Val. Therefore, p.Asp62Val is probably related to the milder phenotype in this patient. Like p.Arg269X, p.Ser610-Asp613del is nearly a functional null, so it is not surprising that this mutation occur in a compound heterozygous manner in patient 4.
In summary, our functional study on eIF2Be mutations recently identified in Chinese VWM patients provides further evidence toward an understanding of the functional defects that result from different mutations. Although we were unable to determine the mechanisms by which the three missense mutations impaired eIF2Be function, we found that they caused at least partial loss of the GEF activity, when part of the eIF2B complex. They seem to impair the intrinsic activity of the eIF2B holocomplex, pointing to interactions between the C-terminal catalytic domain and the more N-terminal regions of eIF2Be in which these mutations occur. Complicated mechanisms, like extensive cross-talk between different domains of eIF2Be and other subunits, and phosphorylation and dephosphorylation of eIF2B and eIF2, appear to be required to regulate eIF2B function. GEF activity of eIF2B may be a preliminary indicator for assessing the severity of functional impairment, and may correlate with phenotype severity in some cases.
